1. Home
  2. ONEG vs CELU Comparison

ONEG vs CELU Comparison

Compare ONEG & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneConstruction Group Limited Ordinary Shares

ONEG

OneConstruction Group Limited Ordinary Shares

HOLD

Current Price

$1.04

Market Cap

18.9M

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$0.80

Market Cap

17.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONEG
CELU
Founded
2021
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
17.3M
IPO Year
2024
2019

Fundamental Metrics

Financial Performance
Metric
ONEG
CELU
Price
$1.04
$0.80
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
39.2K
40.6K
Earning Date
01-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$26,550,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$0.56
52 Week High
$14.95
$4.01

Technical Indicators

Market Signals
Indicator
ONEG
CELU
Relative Strength Index (RSI) 44.61 57.18
Support Level $1.01 $0.69
Resistance Level $1.10 $0.83
Average True Range (ATR) 0.03 0.07
MACD 0.01 0.01
Stochastic Oscillator 41.75 57.19

Price Performance

Historical Comparison
ONEG
CELU

About ONEG OneConstruction Group Limited Ordinary Shares

OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.

About CELU Celularity Inc.

Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.

Share on Social Networks: